Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.
Researchers recommend that future studies examine potential associations between survival and genomic mutations, clinical treatment history, and area deprivation index.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback